1. Scrip
  2. >>Business
  3. >>Strategy

Graffinity/MyoContract: Two Problems, One Solution

 
• By Melanie Senior

By merging with Swiss product development group MyoContract, Germany's Graffinity addresses its two key issues at once: a lack of products, and poor prospects for a viable listing in its home market. Europe's industry needs more such deals, but making them happen isn't easy.

Heidelberg-based Graffinity Pharmaceuticals AG is the latest German biotech to use M&A to morph from a platform into a product company. Until a few weeks ago, Graffinity was a typical German biotech. Founded in 1998 at the height of the country's government-funded BioRegio program, the company was built on the back of a series of clever technologies designed to help others discover and develop drugs.

Since then, the platform technology model has fallen out of favor. Shifting priorities at Big Pharma customers, the commoditization of technology and the painful market correction have led to an...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Strategy

Sanofi Plays It Safer With Blueprint Buy After Bumpy 2025

 
• By Kevin Grogan

But the French major is still keen on early-stage M&A.

BREAKING NEWS: Sanofi Bets $9.5bn To Bag Blueprint

 
• By Kevin Grogan

Buy boosts the French major's immunology pipeline.

Summit’s Ivonescimab Shows Significance On PFS, But Not Overall Survival

 
• By Joseph Haas

In a study intended to show similar benefit in western patients, PD-1/VEGF-targeting ivonescimab met a progression-free survival endpoint, but missed on OS.

Sanofi Bid For Second COPD Approval Hurt By Mixed Itepekimab Data

 
• By Kevin Grogan

One Phase III trial hits but a second study misses by a mile.

More from Business

Summit’s Ivonescimab Shows Significance On PFS, But Not Overall Survival

 
• By Joseph Haas

In a study intended to show similar benefit in western patients, PD-1/VEGF-targeting ivonescimab met a progression-free survival endpoint, but missed on OS.

Sanofi Bid For Second COPD Approval Hurt By Mixed Itepekimab Data

 
• By Kevin Grogan

One Phase III trial hits but a second study misses by a mile.

Astellas Gets CLDN.18.2-Targeted ADC From China’s Evopoint

 
• By Joseph Haas

Astellas will pay $130m up front for near-global rights to a Phase I/II antibody-drug conjugate that will add to its portfolio of CLDN.18.2-targeted drugs, including Vyloy.